Supply Side West, Booth 3537 Thursday, October 17th from [...]

NEW BRUNSWICK, NJ, February 27, 2019 - Natreon, a [...]

A NEW HUMAN CLINICAL STUDY from The Ohio State [...]

A NEW JOINT HEALTH CLINICAL STUDY published in the PubMed listed, Elsevier publication, Asian Journal of Pharmaceutical and Clinical Research, shows Natreon's AyuFlex® (standardized aqueous extract of Terminalia chebula) can significantly improve joint discomfort.

Natreon's Crominex®3+ (Trivalent chromium polyphenolic complex) has been granted GRAS approval. GRAS approval demonstrates Natreon's superiority in tests of safety regarding how it's processed, the products constituents, and exposure to consumers.

Natreon's PrimaVie®, a clinically proven and high quality Purified Shilajit from the Himalayas, significantly increased free and total testosterone levels in healthy volunteers in a new study published in Andrologia. In this randomized, double blind, placebo-controlled study, seventy five healthy volunteers between the ages of 45 and 55 received either 250 mg of PrimaVie® twice daily or identical placebo twice daily for 90 consecutive days.

Natreon's Capros®, a clinically studied and standardized aqueous extract of Phyllanthus emblica, has shown to preserve cardiac tissue during ischemia-reperfusion injury in rats according to a study just published in The Journal of Physiology and Biochemistry.

Natreon, Inc., a leading supplier of scientifically proven Ayurvedic ingredients for the dietary supplement, personal care and food and beverage markets , has received an equity investment from DSM Venturing B.V., the corporate venture capital arm of the global Life Sciences and Materials Sciences company, Royal DSM.

CAPROS® from Natreon gets a U.S.Patent (8,962,576) for endothelial function improvement, a publication of another clinical study from Ohio State University Medical Center on its cardiovascular benefits in the Journal of Medicinal Food and a “No Questions” GRAS letter from FDA.